Boosting drug development through public private partnerships (Laverty OECD P...Per Koch
Presentation from the conference Science diplomacy in action Governance for international science co-operation: the example of Health Research 11-12 February, 2013, arranged by the French and British embassies as a follow up to the OECD STIG project, see http://beyondstig.oecd.org
Boosting drug development through public private partnerships (Laverty OECD P...Per Koch
Presentation from the conference Science diplomacy in action Governance for international science co-operation: the example of Health Research 11-12 February, 2013, arranged by the French and British embassies as a follow up to the OECD STIG project, see http://beyondstig.oecd.org
AMM Meeting, February 2010 Presentation by
Jon Bigelow, CEO, KnowledgePoint 360 Group: "The Evolving Landscape and Challenge of Medical Communications & Education"
Peppers & Rogers Group has created a five-part agenda for establishing a social media practice that will allow payers, providers, pharma companies and others to do see real economic and relationship impact.
Perception of the use of social media for disease awareness in Tunisia Jamel Charabi .MD MBA
Table of Content
I. PROBLEM STUDY
II. WHY THIS RESEARCH?
III. INTRODUCTION
IV. LITERATURE REVIEW
1. SM definitions
2. SM overview
3. SM and marketing
4. Company’s marketing strategy and social media
5. SM and public relation
6. SM and market research
7. SM Metrics
8. SM in Pharmaceutical companies
a. Pharmaceutical marketing Overview
b. Healthcare professionals and social media
c. SM Strategy in pharmaceutical companies
d. Pharmaceutical companies digital targets
e. Social media content impact in pharmaceutical companies
f. Impact of connected objects on Health
g. Best practice of pharmaceutical companies.
h. Regulatory framework
V. SM & TUNISIAN PHARMACEUTICAL COMPANIES
1. Pharmaceutical market Overview
2. Regulation in Tunisian Pharmaceutical market
3. Social media in Tunisian pharmaceutical market
VI. PROBLEM RESEARCH.
VII. METHODOLOGY
VIII. RESULTS
1. How Tunisian pharmaceutical company is facing social media strategies? Also to understand the potential role of social media to increase patient’s awareness
2. To value the impact of social media on company sales performances
3. How Tunisian pharmaceutical companies are using social media in a balanced way seeking for global and local ethics?
X. LIMITS
XI. FUTURE DEVELOPMENT
XII. CONCLUSION
XIII. RECOMMENDATIONS
Information Technology has tremendous potential to transform the health sector. Life sciences can play a leading role in the transformation and in the marketing of life sciences solutions.
[UnitedPatients] and [Project H] are projects concepted and engineered by MobileMan and available as open source on Github.
Social Media and Health Care: A Global PerspectiveSpectrum
On January 27, 2010, Spectrum and Aurora presented a PRSA webinar on how to leverage social media in a regulated industry.
It is important for the health care industry to begin 2010 with a clear vision for embracing social media. In 2009, health care regulators finally started to address the issue - from the FDA's public hearings to the creation of a digital marketing working group by the UK's Pharmaceutical Marketing Society. There is no denying that consumers are constantly turning to the Internet as a source for health information. As communications professionals, we need to understand the opportunities, challenges and threats of the emerging digital world.
The new pharma, customer centric, databased business modelA.R.J. (Rob) Halkes
Customer focus is the core and the basis for all commercial activities for pharma. Customers, physicians and patients expect effective therapies in drugs and support. Sustainable relations with customers are necessary to build trusted relations to create a cooperation to realize that. This tells you how to!
Overview of aspects of pharma's value added services and its primary aspects to deliver them.
Learn what others do and reflect how it's an opportunity for your pharma company..
More Related Content
Similar to Pharma, care and social media how to gain partnership in care
AMM Meeting, February 2010 Presentation by
Jon Bigelow, CEO, KnowledgePoint 360 Group: "The Evolving Landscape and Challenge of Medical Communications & Education"
Peppers & Rogers Group has created a five-part agenda for establishing a social media practice that will allow payers, providers, pharma companies and others to do see real economic and relationship impact.
Perception of the use of social media for disease awareness in Tunisia Jamel Charabi .MD MBA
Table of Content
I. PROBLEM STUDY
II. WHY THIS RESEARCH?
III. INTRODUCTION
IV. LITERATURE REVIEW
1. SM definitions
2. SM overview
3. SM and marketing
4. Company’s marketing strategy and social media
5. SM and public relation
6. SM and market research
7. SM Metrics
8. SM in Pharmaceutical companies
a. Pharmaceutical marketing Overview
b. Healthcare professionals and social media
c. SM Strategy in pharmaceutical companies
d. Pharmaceutical companies digital targets
e. Social media content impact in pharmaceutical companies
f. Impact of connected objects on Health
g. Best practice of pharmaceutical companies.
h. Regulatory framework
V. SM & TUNISIAN PHARMACEUTICAL COMPANIES
1. Pharmaceutical market Overview
2. Regulation in Tunisian Pharmaceutical market
3. Social media in Tunisian pharmaceutical market
VI. PROBLEM RESEARCH.
VII. METHODOLOGY
VIII. RESULTS
1. How Tunisian pharmaceutical company is facing social media strategies? Also to understand the potential role of social media to increase patient’s awareness
2. To value the impact of social media on company sales performances
3. How Tunisian pharmaceutical companies are using social media in a balanced way seeking for global and local ethics?
X. LIMITS
XI. FUTURE DEVELOPMENT
XII. CONCLUSION
XIII. RECOMMENDATIONS
Information Technology has tremendous potential to transform the health sector. Life sciences can play a leading role in the transformation and in the marketing of life sciences solutions.
[UnitedPatients] and [Project H] are projects concepted and engineered by MobileMan and available as open source on Github.
Social Media and Health Care: A Global PerspectiveSpectrum
On January 27, 2010, Spectrum and Aurora presented a PRSA webinar on how to leverage social media in a regulated industry.
It is important for the health care industry to begin 2010 with a clear vision for embracing social media. In 2009, health care regulators finally started to address the issue - from the FDA's public hearings to the creation of a digital marketing working group by the UK's Pharmaceutical Marketing Society. There is no denying that consumers are constantly turning to the Internet as a source for health information. As communications professionals, we need to understand the opportunities, challenges and threats of the emerging digital world.
Similar to Pharma, care and social media how to gain partnership in care (20)
The new pharma, customer centric, databased business modelA.R.J. (Rob) Halkes
Customer focus is the core and the basis for all commercial activities for pharma. Customers, physicians and patients expect effective therapies in drugs and support. Sustainable relations with customers are necessary to build trusted relations to create a cooperation to realize that. This tells you how to!
Overview of aspects of pharma's value added services and its primary aspects to deliver them.
Learn what others do and reflect how it's an opportunity for your pharma company..
"Co-creation" and "Experience Co-Creation" in Health CareA.R.J. (Rob) Halkes
Co-Creation and Experience Co-Creation are two terms which appear usually as puzzling to those who learn about it for the first time. They often think it is like doing or working together. Instead, it is just because of failing cooperation and collaborative work approaches that co-creation is relevant. It is highly successful in many of branches. To health care there are activities and projects that worked with it. But in general the Health Care Business is not easily changing to these unavoidable methods to create personalised care, and an effective eco system and context to enable self management by patients. Here's the introduction.
This is my Keynote presentation to Pharma Forum Russia, St. Petersburg, May 23rd, 2013.
It gives an outline of crucial elements in building a new market approach to different markets.
The Dutch Health Care Reform 2006, a reflection
Having witnessed the movement of the Dutch Health Care Reform (see Wikipedia), it is inspiring to review it to evaluate what processes and forces have initiated the development and formed its course. In discussing possibilities for moving desired developments, we were reflecting on what processes or factors might be used to work along to stimulate innovation and change.
New Pharma approach: from (e-)detailing to customer & patients excellence: a ...A.R.J. (Rob) Halkes
In the demand for a new business model for pharma, the roadmap from current promotion via detailing to a more engaging way to physicians and health care providers, may lead stepwise to improved servicing to physicians and may lead to collaboration to co-create patient care. Role of social media to pharma and multichannel approaches may so find its position in new pharma marketing.
A Dutch Forum, including all relevant parties, has been founded to design and coordinate a process of development from current routines of care with ICD's (implanted cardiac devices) towards telecardiology. Rationale of the construction of the Forum, incl. the description of a frame of references is elaborated.
The differentiation pharma needs in marketing in the advanced markets, Rob Ha...A.R.J. (Rob) Halkes
What differentiation in market approach must pharma be able to do in advanced markets.
How to perform them?
What changes to business?
Rob Halkes, October 2009.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharma, care and social media how to gain partnership in care
1. Pharma, Care and Social Media
How to gain partnership in care –
say “trust”?
Rob Halkes
Pharma Marketing Summit,
Zürich October 13, 2010
value innovation in medical and life sciences
2. Disclosure
> 20 years Health care business development consultant
to all parties in health care, a large part of them being the
pharmaceutical industry in the Netherlands and Europe;
Use a bit of social media
1 Participant in
#hcsmeu –
movement.
www.hcsmeu.com
http://www.slideshare.net/ARJHalk/social-media-and-pharma
3. I. The Dutch Case
II. Social Media?
Development towards improved care?
Experience Co-Creation: integrating health care
patient centred!
2
III. How: Key Customer Focus:
How Pharma creates long term partnership with
health care constituencies:
- differentiated approach to Rx Decision makers
- integrating pharma care in health care 3.0
4. General Trends
Pharma market Average
Western Europe
Actual Market Conditions
the Netherlands
Declining access to prescribers;
Image pharmaceutical industry;
More and more strict regulation of
3
Pharma promotion
Cost of health care is high on The
political agenda: price erosion Netherlands
Pressure on prescribing generics
International
No large blockbusters
Sales forces rationalization
Centralization
Pharma at the “Tipping Point”
Search for new business models
5. 4
Roland Berger: Penny wise, Pound Foolish? May 2010
6. The Dutch Health care market Privatising health care market
2006: Liberalisation Health Care Insurance Customer
Market, Health Care Health care
Insurance provision
• Power and direction of market
market market
development to HC Insurance Co’s:
• Buying power: Pharma tenders, Health Care Health Care
Insurance Co. providers
• Selection of health care providers,
Health Care
• Towards integrated care; Contracting market
5
Liberalisation of prof. medical activities in clinic:
Non-negotiable and negotiable (A & B segment) med. activities,
System of DRG (diagnose related group of act.);
Focus and concentration of care at local GP-level
Integrated care for chronic conditions at health care groups –
towards integrated cost of care (Outcome pricing?);
Allowance for private investments and profit;
Still national Budget/ Standard package of Care Insurance ↓;
7. Primary care: GP practice consolidation
= GP
6 = pharmacist
= nurse practitioner.
1970 2008 = other HC profess.
(51%)
Group+ Health
Solo (20%) Duo (29%) Group
Pharmacist Centre
8. Health Care groups focus on development of chronic care
(Diabetes, COPD, CVRM, etc)
– so as to negotiate with
the heath care insurance co’s.
N= +/-100
HC- HC- HC-
group group group
7
Structures on
Waar-
three levels A- 1e lijns
HOED neem
HOED centrum
groep
GP GP GP
GP GP GP GP GP GP
9. What is this with Social Media?
8
Crossweb.nl
chainconnection.com
10. And What could you do with them?
Publish
MMO Share
9 Social
Discuss
Games
Virtual Social
Worlds Networks
Micro
Livecast
blog
Life
stream
bartvandecasteel.wordpress.com
11. Create
Transactional Desired
Occasional Outcomes
Impersonal Continuous
Short-term Intimate
Loyal
Web 1.0 Web 2.0 Web 3.0
10
- Exposure - Interactive - Focus
- One way - Sourcing - Collaborative
- Information - Dialogue - Commitment
- Public - Public/Private - Together
- Private
Communicate Engage / Relate Collaborate
partner
Listen Engage
12. What party does not use Social Media?
All parties in caring for health and health care use social
media:
Health care providers,
Health care providing organisations: hospitals,
11 pharmacists, GP, local HC centres, etc. etc.
Health Professional organisations,
The government and Ministries of Health,
Health Authorities;
Health Care insurance agencies;
The supplying industry;
Health care publishing agencies;
Patients and patients organisations, and
Yes, Pharmaceutical industry as well…
And each party benefits from them too!
13. But: Pharma is under scrutiny!
Web1.0 and Web2.0 is subsumed under public
Information, so under scrutiny from promotion and
advertising rules;
Accountability;
12
Fulfilling Regulatory Requirements;
Posting Corrective Information;
Links;
Adverse Event Reporting;
Sandra van Nuland, Zamire Damen
April 2010
14. How to tackle the obligations?
Beyond current and existing
systems for pharmacovigilance:
Monitor all social media and internet
mentions of the company and brands,
(Boehringer Ingelheim);
13
Publish guidelines to be followed
internally and to advise external ppl. (Roche);
Design, pilot and test!
Attend to the ROI of things..
Even better to “Return on Health”
ROH!
FDA/ EMEA is watching!
15. Starting opinions
re.: Pharma & Soc. Med.:
- Twitter & non T
- Pharma & non Ph
14
16. Lessons learned in Pharma2.0:
There are structural and fundamental changes in communication
in going
from “advertising” to “engaging”: “Do not promote”…
Form product oriented to patient centred:
15
Listen more than talk;
Be transparent and honest;
Be authentic;
Be personal;
Information ≠ informing
(Quote by Hilda Bastian, IQWiG, Germany)
Pfizer’s principles in online information
Rene Neubach, October 2010
17. Pharma 1.0 Pharma 2.0 Pharma 3.0
- Exposure - Interactive - Focus
- One way - Sourcing - Collaborate
- Information - Dialogue - Commit
- Public - Public Private - Patient’s
Privacy
Communicate Relate Collaborate
One way Two way Experience
16 information Communication Co-Creation
- - -
“Access” To interact Collaboration
- - Partnership to
Detailing E-detailing health care
Conferencing Email campaigns development
Educating Building -
communities Improving
Health Care
Outcomes
18. “Experience Co-Creation in Care”
Imagine structuring and solving problems in process
of delivery and implementing the therapy
Other
Friends Patients Coach
Etc.
Family
Patient
17
GP
Nurse Etc.
Ph Logistics
Industry HCI
19. How does EC3 support HCproviders
in their medical profession
It supports them with support to their patients without a
great deal of investment or energy;
It helps them reach goals in health (e.g. compliance) more
18
easily;
It distinguishes their business from other health care
providers;
They are enabled in cooperation with other stakeholders
without competition between them;
Their professional needs of caring for health care will be
satisfied.
20. How does EC3 help patients
They find a trusted and reliable, easily
accessible health care context that satisfies
their needs in their care for health!
Their care provision is integrated, structured
19 and organised for all related health care
provider and stakeholders;
They have all sorts of information and
support facilities that their providers also are
accustomed to;
They feel a sense of trust and peace of mind,
because there’s always a human helping
hand and listening ear – one click away.
21. Pharma: Add to your promotion:
“Key Customer Focus”
1. From promotion to Health Care Support and Health care
development:
Value proposition by Integrated Offering;
2. From Approaching Individual Prescribers to
20
Health Care Groups:
Segmentation of Potential, Accessibility and Feasibility;
3. From promotion only, to collaboration and on to Partnership
Operational levels of cooperation;
4. From a standard approach to all, towards Differentiation of
Accounts;
22. Development of integrated
value proposition
Product Medicine, Drug profile Product
Rx
Core: Pharmaceutical and Information on
Pharma economically characteristics features,
functionality and effects
21 Focus on adequate use Augmented brand
1st Layer
For the right patient Support and service by
in the right condition marketing tools
through different channels
A. Professional Support of Value proposition
HC professionals A. Patient oriented health care
2nd for the patient activities by Health Care
Layer Professionals
B. Cooperation and synergy
between co-acting B. Increasing HC effects by
health care providers improvement of care and health
processes
23. Possibilities and perspectives for EC3
Communication and information to patients
Self knowledge tests on condition and implications
Patient coaching on initial experience of diagnosis
Support to first drug issue
Peer support and coaching
22 Patient partnerships
Integrated connection for care processes
Close cooperation with pharmacists, health care providers
and other stakeholders in care
Compliance support
Behavioural change and life style support
Food and nutrition information
Information on multi drug interaction issues
From first support to problems in use
Remote diagnosis
Patient profiling
24. Development of value proposition
Key to an effective value proposition of Pharma, is:
• A USP that opens doors to gain access;
• Added value to health care professionals and health care payers;
• Added value in terms of improvement of patient care;
• A means to develop and sustain a long term relationship.
Guidelines to the development of the value proposition:
• Define major steps of treatment to the disease to define the total
cycle of care to the patient
23 (from awareness and diagnosis to treatment and recovery);
• Develop Care for the disease as integrated HC-approach:
• Patient support programmes;
So much to gain by elaborating on:
providing information ≠ informing
• Various elements to structure the health care process by health
care providers;
• Various elements that improve care but do not extend providers’
action or time;
• Allow for various levels of offering depending on sales potential;
• Make an inventory of the needs of HC-groups with care for the
disease treatment;
• Develop business case for HC group
25. How to know the networks of influence around Rx
24
• Data collection (relevant data and keeping them up to date)
• Registration (integrating and aligning information,
report and relation management systems)
• Segmentation (segmenting account groups)
• Targeting(selecting and focusing on access and sustain
relationship)
Not just on potential of individuals, but of groups,
their accessibility and the feasibility for success
to differentiate
26. To determine 1. Analyse and Profile
Decision makers’ differentiating
Selection and
segmentation of
Potential characteristics on Accessibility Accessibility
Variables
and Accessibility
2. Determine main dimensions
for distinguishable
approach
Determine feasibility of success
Distinguish categories
Test Define and decide
on Routines and
25 Content of approach
3.What steps in Account
development and management
How to implement
Create national and
local Health Care
Institutions - Focus on content
to create
guiding and 4. Upon analysis
Collaboration for
sponsoring create specific value propositions /
Health care
Health Care incentives
development,
Development by gradually moving
your partnerships into optimising
patient care
5. Implementation
27. Account Based Marketing
Everything must be seen fit to the account!
Segment type
Data and characteristics Targeting
Effects and output
Investment: volume
26
Monitoring Account
Commercial action plan
Related professional functions
Process structures
Account management
Information and
Means and channels communication
28. To create cooperation: Steps towards
Integrated care and Partnership
4. Targeting
health care
Contract to integrated care with more parties:
Level of Multi party deal on outcomes outcome directed, long term,
Health Outcomes With more
Integration stakeholders In development and improvement.
Value
Value
3. Commitment Design Contract to design and implement
27 and realisation of
Partner to joint tailor made Based on customer knowledge,
Creation
Creation
Results solutions
Level and in co-makership.
2. Cooperation to
Commitment on Implementation Contract:
Level of realize
mutual effort goals Agreement at DMU level, on effort.
Cooperation
1. Sponsor contract:
Service Offering These are our
Level of services Utilising capacity,
Sponsoring
Transaction Experience and “know how”.
29. “Key Customer Focus”
1. Learn which accounts to focus on, depending on
accessibility, potential and feasibility of success;
2. Teach the field forces how to differentiate in their account
management;
3. Define and create value propositions that adopt the
28 customers’ desires and demands for results of the
relationship with pharma and for health outcomes,
into EC3;
4. Teach marketing and field force to step beyond promotion
and develop cooperation towards partnership with health
constituencies;
5. Decide strategically your company’s position to health care;
6. Develop a business cycle to budget and implement, and to
adopt to changing market conditions.
30. USP in pharma field forces
Integrated Offering Development of
Integrated Health Partnership
and Pharma Care in stages
29
Differentiated Business Model
Account Specification
Based Marketing
32. References
31
Never hire an expert: http://timbaker.info/never-hire-a-social-media-expert/;
Rob Halkes, Social Media and Pharma, Selling Sickness, Amsterdam, & October 2010:
http://slidesha.re/acjF84
Pennywise, pound foolish? Accessible, affordable and high quality pharmaceutical healthcare for the
Dutch patient – Today tomorrow. Position Paper, Roland Berger, 2010.
Quote by Hilda Bastian, IQWiG, Germany: Independent Patient Information, Selling Sickness Conference
A’dam 7 October 2010, http://slidesha.re/avDQrK
Rene Neubach,Pfizer: How to successfully launch online programmes and engage with HCPs, Digipharm
October 2010
Judith von Gordon-Weichelt, Head of Media & PR, Boehringer Ingelheim GmbH, Social Media Monitoring,
Digipharm Conference London, October 2010;
Ernst & Young, Progressions Pharma 3.0, Global Pharmaceutical Industry report, Basel May 2010.
Rob Halkes, Experience Co-Creation in Health Care (EC3), http://wp-pharma.waardeinnovatie.nl/?p=183
33. Van Spaendonck’s BU “Value Innovation in Medical and life Sciences”
is a focused consultancy firm.
Van Spaendonck management consultancy supports and directs parties and professionals to
proper choices and processes to create and develop their USP, a better market position and performance.
In the dynamics of health care systems, pharmaceutical industry, health care insurers, social parties,
and health care professionals will be challenged more and more to their added value.
The business unit “Value innovation for Medical and Life Sciences,”
has the needed expertise and experience to initiate and develop processes and clinics for health care, marketing,
sales and management systems, professional development, and strategic organisational change.
20 years of consultancy expertise to pharmaceutical and medical industry, life sciences and health care.
Actual research and publications in health care and marketing developments.
Rob Halkes
BU Van Spaendonck – Value innovation in Medical and Life Sciences
T +31 418 578000
M+31 653 420722
E r.halkes@VanSpaendonck.nl G.E.H. Tutein Noltheniuslaan 7
W www.medicalandpharmamarketing.com 4181AS Waardenburg
T www.twitter.com/rohal the Netherlands
value innovation in medical and life sciences